1
|
Wang J, Yen R, Beck AG, Aggarwal P, Kong M, Hayes M, Jabri S, Greshock TJ, Hettiarachchi K. Predictions of Chromatography Methods by Chemical Structure Similarity to Accelerate High-Throughput Medicinal Chemistry. ACS Med Chem Lett 2024; 15:1396-1401. [PMID: 39140053 PMCID: PMC11318006 DOI: 10.1021/acsmedchemlett.4c00145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2024] [Revised: 07/01/2024] [Accepted: 07/09/2024] [Indexed: 08/15/2024] Open
Abstract
We introduce a new workflow that relies heavily on chemical quantitative structure-retention relationship (QSRR) models to accelerate method development for micro/mini-scale high-throughput purification (HTP). This provides faster access to new active pharmaceutical ingredients (APIs) through high-throughput experimentation (HTE). By comparing fingerprint structural similarity (e.g., Tanimoto index) with small training data sets containing a few hundred diverse small molecule antagonists of a lipid metabolizing enzyme, we can predict retention time (RT) of new compounds. Machine learning (ML) helps to identify optimal separation conditions for purification without performing the traditional crude QC step involving ultrahigh performance liquid chromatography (UHPLC) analyses of each compound. This green-chemistry approach with the use of predictive tools reduces cost and significantly shortens the design-make-test (DMT) cycle of new drugs by way of HTE.
Collapse
Affiliation(s)
- Jun Wang
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Rose Yen
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Armen G. Beck
- Analytical
Research & Development, Merck &
Co., Inc., 126 E. Lincoln
Ave., Rahway, New Jersey 07065, United States
| | - Pankaj Aggarwal
- Analytical
Research & Development, Merck &
Co., Inc., 126 E. Lincoln
Ave., Rahway, New Jersey 07065, United States
| | - May Kong
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Michael Hayes
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Salman Jabri
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Thomas J. Greshock
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| | - Kanaka Hettiarachchi
- Discovery
Chemistry, Merck & Co., Inc., 213. E. Grand Ave., South San Francisco, California 94080, United States
| |
Collapse
|
2
|
Liu C, Zhang H. Data processing for high-throughput mass spectrometry in drug discovery. Expert Opin Drug Discov 2024; 19:815-825. [PMID: 38785418 DOI: 10.1080/17460441.2024.2354871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2024] [Accepted: 05/08/2024] [Indexed: 05/25/2024]
Abstract
INTRODUCTION High-throughput mass spectrometry that could deliver > 10 times faster sample readout speed than traditional LC-based platforms has emerged as a powerful analytical technique, enabling the rapid analysis of complex biological samples. This increased speed of MS data acquisition has brought a critical demand for automatic data processing capabilities that should match or surpass the speed of data acquisition. Those data processing capabilities should serve the different requirements of drug discovery workflows. AREAS COVERED This paper introduced the key steps of the automatic data processing workflows for high-throughput MS technologies. Specific examples and requirements are detailed for different drug discovery applications. EXPERT OPINION The demand for automatic data processing in high-throughput mass spectrometry is driven by the need to keep pace with the accelerated speed of data acquisition. The seamless integration of processing capabilities with LIMS, efficient data review mechanisms, and the exploration of future features such as real-time feedback, automatic method optimization, and AI model training is crucial for advancing the drug discovery field. As technology continues to evolve, the synergy between high-throughput mass spectrometry and intelligent data processing will undoubtedly play a pivotal role in shaping the future of high-throughput drug discovery applications.
Collapse
Affiliation(s)
| | - Hui Zhang
- Iambic Therapeutics, San Diego, CA, USA
| |
Collapse
|
3
|
Wleklinski M, Carpenter PM, Dykstra KD, Donofrio A, Nowak T, Krska SW, Ferguson RD. Parallel purification of microscale libraries via automated solid phase extraction. SLAS Technol 2024; 29:100126. [PMID: 38423211 DOI: 10.1016/j.slast.2024.100126] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2023] [Revised: 01/30/2024] [Accepted: 02/25/2024] [Indexed: 03/02/2024]
Abstract
High-throughput experimentation (HTE) has become more widely utilized in drug discovery for rapid reaction optimization and generation of large synthetic compound arrays. While this has accelerated medicinal chemistry design, make, test (DMT) iterations, the bottleneck of purification persists, consuming time and resources. Herein we describe a general parallel purification approach based on solid phase extraction (SPE) that provides a more efficient and sustainable workflow producing compound libraries with significantly upgraded purity. This robust, user-friendly workflow is fully automated and integrated with HTE library synthesis, as demonstrated by its application to a diverse parallel library compound array generated via amide-bond coupling in HTE microscale format.
Collapse
Affiliation(s)
- Michael Wleklinski
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Paige M Carpenter
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Kevin D Dykstra
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Anthony Donofrio
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Timothy Nowak
- Department of Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Shane W Krska
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA
| | - Ronald D Ferguson
- Department of Discovery Chemistry, Merck & Co., Inc., Rahway, NJ 07065, USA.
| |
Collapse
|
4
|
Brocklehurst CE, Altmann E, Bon C, Davis H, Dunstan D, Ertl P, Ginsburg-Moraff C, Grob J, Gosling DJ, Lapointe G, Marziale AN, Mues H, Palmieri M, Racine S, Robinson RI, Springer C, Tan K, Ulmer W, Wyler R. MicroCycle: An Integrated and Automated Platform to Accelerate Drug Discovery. J Med Chem 2024; 67:2118-2128. [PMID: 38270627 DOI: 10.1021/acs.jmedchem.3c02029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2024]
Abstract
We herein describe the development and application of a modular technology platform which incorporates recent advances in plate-based microscale chemistry, automated purification, in situ quantification, and robotic liquid handling to enable rapid access to high-quality chemical matter already formatted for assays. In using microscale chemistry and thus consuming minimal chemical matter, the platform is not only efficient but also follows green chemistry principles. By reorienting existing high-throughput assay technology, the platform can generate a full package of relevant data on each set of compounds in every learning cycle. The multiparameter exploration of chemical and property space is hereby driven by active learning models. The enhanced compound optimization process is generating knowledge for drug discovery projects in a time frame never before possible.
Collapse
Affiliation(s)
- Cara E Brocklehurst
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Eva Altmann
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Corentin Bon
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Holly Davis
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - David Dunstan
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - Peter Ertl
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Carol Ginsburg-Moraff
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - Jonathan Grob
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - Daniel J Gosling
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Guillaume Lapointe
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Alexander N Marziale
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Heinrich Mues
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Marco Palmieri
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Sophie Racine
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| | - Richard I Robinson
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - Clayton Springer
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - Kian Tan
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - William Ulmer
- Global Discovery Chemistry, Novartis Biomedical Research, Cambridge, Massachusetts 02139, United States
| | - René Wyler
- Global Discovery Chemistry, Novartis Biomedical Research, Novartis Pharma AG, Basel 4033, Switzerland
| |
Collapse
|
5
|
Götz J, Jackl MK, Jindakun C, Marziale AN, André J, Gosling DJ, Springer C, Palmieri M, Reck M, Luneau A, Brocklehurst CE, Bode JW. High-throughput synthesis provides data for predicting molecular properties and reaction success. SCIENCE ADVANCES 2023; 9:eadj2314. [PMID: 37889964 PMCID: PMC10610918 DOI: 10.1126/sciadv.adj2314] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 09/26/2023] [Indexed: 10/29/2023]
Abstract
The generation of attractive scaffolds for drug discovery efforts requires the expeditious synthesis of diverse analogues from readily available building blocks. This endeavor necessitates a trade-off between diversity and ease of access and is further complicated by uncertainty about the synthesizability and pharmacokinetic properties of the resulting compounds. Here, we document a platform that leverages photocatalytic N-heterocycle synthesis, high-throughput experimentation, automated purification, and physicochemical assays on 1152 discrete reactions. Together, the data generated allow rational predictions of the synthesizability of stereochemically diverse C-substituted N-saturated heterocycles with deep learning and reveal unexpected trends on the relationship between structure and properties. This study exemplifies how organic chemists can exploit state-of-the-art technologies to markedly increase throughput and confidence in the preparation of drug-like molecules.
Collapse
Affiliation(s)
- Julian Götz
- Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zürich, Switzerland
| | - Moritz K. Jackl
- Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zürich, Switzerland
| | - Chalupat Jindakun
- Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zürich, Switzerland
| | - Alexander N. Marziale
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Jérôme André
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Daniel J. Gosling
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Clayton Springer
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, Cambridge, MA 02139, USA
| | - Marco Palmieri
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Marcel Reck
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Alexandre Luneau
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Cara E. Brocklehurst
- Global Discovery Chemistry, Novartis Institutes for Biomedical Research, Novartis Pharma AG, 4056 Basel, Switzerland
| | - Jeffrey W. Bode
- Laboratory of Organic Chemistry, Department of Chemistry and Applied Biosciences, ETH Zürich, 8093 Zürich, Switzerland
| |
Collapse
|
6
|
Jones M, Goodyear RL. High-Throughput Purification in Drug Discovery: Scaling New Heights of Productivity. ACS Med Chem Lett 2023; 14:916-919. [PMID: 37465307 PMCID: PMC10351054 DOI: 10.1021/acsmedchemlett.3c00073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Accepted: 05/16/2023] [Indexed: 07/20/2023] Open
Abstract
With the "low hanging fruit" of early drug discovery gone, pharmaceutical companies are increasingly turning to developing high-throughput synthetic platforms capable of greatly shortening the design-make-test cycle of new drugs. Purification has long been considered the bottleneck of this procedure; however, new technologies and systems are now being integrated into these high-throughput synthetic workflows, providing compounds of high purity capable of being used directly in biological screening.
Collapse
Affiliation(s)
- Mark Jones
- Liverpool ChiroChem Ltd, The Heath Business & Technical
Park, Runcorn, Cheshire WA7 4QX, U.K.
| | - Ross L. Goodyear
- Liverpool ChiroChem Ltd, The Heath Business & Technical
Park, Runcorn, Cheshire WA7 4QX, U.K.
| |
Collapse
|